Skip to content
MARKETS / NASDAQ / TENX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Tenax Therapeutics, Inc. TENX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-52.6M
Growth
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -52.6
4M8M-20M-40M20102012201420172019202120232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2014 · Operating -30062.8% · Net -28571.6%
5000%10000%-10000%-20000%-30000%20102012201420172019202120232025
ROE
FY2025 · ROE -55.6%
100%200%300%-200%-400%-600%20102012201420172019202120232025

Each USD of equity lost 56 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -11.4
-8M20102012201420172019202120232025

Total assetsUSD 104.2M
EquityUSD 97.1M
CashUSD 97.6M
Current ratio14.56×

Equity funds 93% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620142013201220112010
Revenue $B0.00.0·······0.00.00.00.00.00.0
Operating income $B−0.1−0.0−0.00.0−0.00.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.00.0
EBITDA $B··−0.00.0−0.00.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0··
Income tax $B0.00.00.00.00.00.00.00.00.0−0.00.00.0···
Net income $B−0.1−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
Free cash flow $B···−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.34−1.15−31.04·−1.58−0.95−1.35−9.04−6.27−31.24−0.50−2.71−6.68−14.070.45
Dividend / sh $···············
Payout %···············
ROE %−55.6−35.2−160.8385.1−732.2−234.6−108.0−137.0−67.9−113.3−18.4−48.2···
Shares out B0.010.000.000.000.000.010.010.000.000.000.030.030.000.000.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures · 6 divergences in 68 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 6 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 27 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures6 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image